Table 1.
Cardiovascular adverse events grouped into 8 narrow categories of SMQs according to MedDRA 24.0.
Fig 1.
The bar plot shows the number of reports with cardiovascular AEs for different JAKinibs treatment.
Fig 2.
The time trend of cardiovascular AEs.
Table 2.
The clinical characteristics of cardiovascular AEs.
Fig 3.
Disproportionality analysis of JAKinibs-related cardiovascular AEs compared to the full database(ROR: reporting odds ratio, ROR025: The lower limit of the 95% CI for ROR, ROR075: The upper limit of the 95%CI for ROR).
Fig 4.
Disproportionality analysis of JAKinibs-related cardiovascular AEs compared to TNF-α inhibitors(ROR: reporting odds ratio, ROR025: The lower limit of the 95% CI for ROR, ROR075: The upper limit of the 95%CI for ROR).